AC Immune SA宣布，其针对阿尔茨海默病治疗的二期临床试验（代号Retain）的招募工作已自愿暂停。公司强调，这一决定并非基于任何新的安全性问题或不良事件，而是出于内部策略考量。
此次暂停为临时性措施，旨在优化试验流程与资源配置。AC Immune SA表示，将根据后续评估结果决定何时重启患者招募工作，并承诺及时向投资者及监管机构通报进展。
AC Immune SA宣布，其针对阿尔茨海默病治疗的二期临床试验（代号Retain）的招募工作已自愿暂停。公司强调，这一决定并非基于任何新的安全性问题或不良事件，而是出于内部策略考量。
此次暂停为临时性措施，旨在优化试验流程与资源配置。AC Immune SA表示，将根据后续评估结果决定何时重启患者招募工作，并承诺及时向投资者及监管机构通报进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.